Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Jaswinder P. Singh

Hematology Oncology | Hematology | Oncology
Western Missouri Medical Center
403 Burkarth Rd, 
Warrensburg, MO 
Accepting New Patients

Distinguished in WT1-Related Wilms Tumor Syndromes
Western Missouri Medical Center
403 Burkarth Rd, 
Warrensburg, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jaswinder Singh is a Hematologist Oncology specialist and a Hematologist in Warrensburg, Missouri. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Osteotomy, and Vitrectomy. Dr. Singh is currently accepting new patients.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Cass Regional Medical Center
Western Missouri Medical Center
Research Medical Center
Bates County Memorial Hospital
Golden Valley Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

WESTERN MISSOURI MEDICAL CENTER
403 Burkarth Rd, Warrensburg, MO 64093
Call: 660-747-2500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
Enrollment Status: No_longer_available
Publish Date: April 12, 2024
Intervention Type: Drug
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
Enrollment Status: Withdrawn
Publish Date: February 15, 2019
Intervention Type: Other, Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

27 Total Publications

Outcomes of Surgical Management of Late Presenting Intra-Articular Distal Femoral Physeal Fracture: A Multicentric Retrospective Case Series.
Outcomes of Surgical Management of Late Presenting Intra-Articular Distal Femoral Physeal Fracture: A Multicentric Retrospective Case Series.
Journal: Indian journal of orthopaedics
Published: November 11, 2024
View All 27 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rahul A. Parikh
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rahul A. Parikh
Oncology | Hematology | Hematology Oncology

University Of Kansas Hospital Authority

2650 Shawnee Mission Pkwy, 
Westwood, KS 
 (51.5 miles away)
913-588-7750
Languages Spoken:
English, Hindi, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rahul Parikh is an Oncologist and a Hematologist in Westwood, Kansas. Dr. Parikh is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, and Bladder Cancer. Dr. Parikh is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeremy R. Flanagan
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeremy R. Flanagan
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

8700 N Green Hiils Rd, 
Kansas City, MO 
 (59.3 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Flanagan is a Hematologist Oncology specialist and a Hematologist in Kansas City, Missouri. Dr. Flanagan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Flanagan is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nisreen A. Haideri
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nisreen A. Haideri
Oncology | Hematology Oncology | Hematology

Midwest Oncology Associates LLC

2316 E Meyer Blvd, Research Medical Center, 
Kansas City, MO 
 (48.0 miles away)
816-276-4000
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nisreen Haideri is an Oncologist and a Hematologist Oncology provider in Kansas City, Missouri. Dr. Haideri is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes. Dr. Haideri is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Mountain Sickness
      Dr. Singh is
      Distinguished
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Singh is
      Distinguished
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Singh is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Singh is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Singh is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anemia
      Dr. Singh is
      Distinguished
      . Learn about Anemia.
      See more Anemia experts
    View All 52 Distinguished Conditions
    • Advanced
    • Acute Eosinophilic Pneumonia
      Dr. Singh is
      Advanced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Adult Soft Tissue Sarcoma
      Dr. Singh is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Singh is
      Advanced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Ampullary Cancer
      Dr. Singh is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Antiphospholipid Syndrome
      Dr. Singh is
      Advanced
      . Learn about Antiphospholipid Syndrome.
      See more Antiphospholipid Syndrome experts
    • Appendix Cancer
      Dr. Singh is
      Advanced
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    View All 95 Advanced Conditions
    • Experienced
    • Accessory Pancreas
      Dr. Singh is
      Experienced
      . Learn about Accessory Pancreas.
      See more Accessory Pancreas experts
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Singh is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acquired Agranulocytosis
      Dr. Singh is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acquired Hemophilia
      Dr. Singh is
      Experienced
      . Learn about Acquired Hemophilia.
      See more Acquired Hemophilia experts
    • Acute Hepatic Porphyria (AHP)
      Dr. Singh is
      Experienced
      . Learn about Acute Hepatic Porphyria (AHP).
      See more Acute Hepatic Porphyria (AHP) experts
    • Acute Intermittent Porphyria
      Dr. Singh is
      Experienced
      . Learn about Acute Intermittent Porphyria.
      See more Acute Intermittent Porphyria experts
    View All 201 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved